Melike AYDOĞDU, Serap ANNETTE AKGÜR, Eda AÇIKGÖZ, Ümmü GÜVEN, Yusuf Ali ALTUNCI, Fahriye DÜZAĞAÇ, Aslı ATASOY, Nebile DAĞLIOĞLU

New Psychoactive Substance 5-MeO-MiPT In vivo Acute Toxicity and Hystotoxicological Study

Background: The hallucinogenic tryptamine analog 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT) causes social problems worldwide. There are several studies on the metabolism; however, not more studies were found in the literature on acute toxicity.Aims: To report the acute toxicity of 5-MeO-MiPT in mice, followed by quantitative toxicological analysis of blood and organs, hystotoxicological and immunohistochemical analysis of tissues and cells.Study design: Animal experimentMethods: In vivo experiments were performed using CD1 adult female mice (n=26). Animals were caged in 4 groups randomly. First group was a control (n=3). Second group was vehicle control (n=3) and injected 150 μL of blank solution (50% dimethyl sulfoxide in saline /0.9% of NaCl). While for acute toxicity experiments, 5-MeO-MiPT was added to a blank solution in order to obtain a dose of 0.27 mg/kg in 150 μL injection (n=10) and the last group were injected 2.7 mg/kg 5-MeO-MiPT in a 150 μL injection (n=10). Quantitative toxicological analysis, hystotoxicological and immunohistochemical analysis were performed.Results: In the toxicological analysis, 5-MeO-MiPT was found negative in biological samples which were control, vehicle control, and 0.27 mg/kg dose mice groups. 5-MeO-MiPT was found 2.7-13.4 ng/mL in blood, 11-29 ng/g in kidney, 15.2-108.3 ng/g in liver, and 1.5-40.6 ng/g in the brain in 2,7 mg/kg injected group. In a low dose of the 5-MeO-MiPT liver section, compared with normal tissues, the difference in staining was statistically significant (p

PDF

___

1. Soussan C, Kjellgren A. The users of Novel Psychoactive Substances: Online survey about their characteristics, attitudes and motivations. Int J Drug Policy 2016;32:77-84. [Crossref]
2. Liechti M. Novel psychoactive substances (designer drugs): Overview and pharmacology of modulators of monoamine signaling. Swiss Med Wkly 2015;145:w14043.doi: 10.4414/smw.2015.14043. [Crossref]
3. Nagai F, Nonaka R, Satoh Hisashi Kamimura K. The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 2007;559:132-7. [Crossref]
4. Deluca P, Davey Z, Corazza O, Furia LD, Farre M, Flesland LH, et al. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Prog NeuroPsychopharmacology Biol Psychiatry 2012;39:221-6. [Crossref]
5. Hondebrink L, Nugteren-van Lonkhuyzen JJ, Van Der Gouwe D, Brunt TM. Monitoring new psychoactive substances (NPS) in the Netherlands: Data from the drug market and the Poisons Information Centre. Drug Alcohol Depend 2015;147:109-15. [Crossref]
6. Corazza O, Assi S, Malekianragheb S, Beni MN, Bigdeli I, Aslanpour Z, et al. Monitoring novel psychoactive substances allegedly offered online for sale in Persian and Arabic languages. Int J Drug Policy 2014;25:724-6. [Crossref]
7. Göl E, Çok I. New psychoactive substances in Turkey: Narcotics cases assessed by the Council of Forensic Medicine between 2016 and 2017 in Ankara, Turkey. Forensic Sci Int 2019;294:113-23. [Crossref]
8. Hill SL, Thomas SHL. Clinical toxicology of newer recreational drugs. Clin Toxicol. 2011;49:705-19. [Crossref]
9. Araújo AM, Carvalho F, Bastos M de L, Guedes de Pinho P, Carvalho M. The hallucinogenic world of tryptamines: an updated review. Arch Toxicol 2015;89:1151-73. [Crossref]
10. Shulgin A, Shulgin A. TIHKAL. The Continuation.; 1st ed. Berkeley, CA: Dan Joy; 1997.
11. Tittarelli R, Mannocchi G, Pantano F, Romolo F. Recreational use, analysis and toxicity of tryptamines. Curr Neuropharmacol 2014;13:26-46. [Crossref]
12. Brandt SD, Martins CPB. Analytical methods for psychoactive N,N-dialkylated tryptamines. TrAC - Trends Anal Chem 2010;29:858-69. [Crossref]
13. Grafinger KE, Hädener M, König S, Weinmann W. Study of the in vitro and in vivo metabolism of the tryptamine 5-MeO-MiPT using human liver microsomes and real case samples. Drug Test Anal 2018;10:562-74. [Crossref]
14. Shimizu E, Watanabe H, Kojima T, Hagiwara H, Fujisaki M, Miyatake R et al. Combined intoxication with methylone and 5-MeO-MiPT. Prog Neuro-Psychopharmacology Biol Psychiatry 2007;31:288-91. [Crossref]
15. Rickli A, Moning OD, Hoener MC, Liechti ME. Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol. 2016;26:1327-37. [Crossref]
16. Fantegrossi WE, Harrington AW, Kiessel CL, Eckler JR, Rabin RA, Winter JC, et al. Hallucinogenlike actions of 5-methoxy-N, N-diisopropyltryptamine in mice and rats. Pharmacol Biochem Behav 2006;83:122-9. [Crossref]
17. Van Hout MC, Hearne E. New psychoactive substances (NPS) on cryptomarket fora: An exploratory study of characteristics of forum activity between NPS buyers and vendors. Int J Drug Policy 2017;40:102-10. [Crossref]
18. Nonaka R, Nagi F, Ogata A, Satoh K. In vitro screening of psychoactive drugs by [35 S] GTP gamma S binding in rat. Biol Pharm Bull 2007;30:2328-33. [Crossref]
19. Johansson A, Lindstedt D, Roman M, Thelander G, Nielsen EI, Lennborn U et al. A non-fatal intoxication and seven deaths involving the dissociative drug 3-MeO-PCP. Forensic Sci Int 2017;275:76-82. [Crossref]
20. Fabregat-Safont D, Barneo-Muñoz M, Martinez-Garcia F, Sancho J V., Hernández F, Ibáñez M. Proposal of 5-methoxy-N-methyl-N-isopropyltryptamine consumption biomarkers through identification of in vivo metabolites from mice. J Chromatogr A 2017;1508:95-105. [Crossref]
21. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. PLoS Biol 2010; 29;8:e1000412 [Crossref]
22. Kamata T, Katagi M, Tsuchihashi H. Metabolism and toxicological analyses of hallucinogenic tryptamine analogues being abused in Japan. Forensic Toxicol 2010;28:1-8. [Crossref]
23. Herrera F, Martin V, Carrera P, Rodriguez-Blanco J, Rodriguez C, Antolín I. Tryptamine induces cell death with ultrastructural features of autophagy in neurons and glia: Possible relevance for neurodegenerative disorders. Anat Rec A Discov Mol Cell Evol Biol 2006;288:1026-30. [Crossref]
24. Noworyta-Sokołowska K, Kamińska K, Kreiner G, Rogóż Z, Gołembiowska K. Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats. Neurotox Res 2016;30:606-19. [Crossref]
25. Elmore S. Apoptosis: A review of programmed cell death. Toxicol Pathol 2007;35:495-516. [Crossref]
26. Yang W, Guo C, Fan Hui, Liu F, Yin M. Studying the mRNA and protein expression pattern of apoptosis and autophagy-related genes in renal cell carcinoma. Int J Clin Exp Med 2017;10:14593-8.
27. Seif El-Din SH, El-Lakkany NM, Salem MB, Hammam OA, Saleh S, Botros SS. Resveratrol mitigates hepatic injury in rats by regulating oxidative stress, nuclear factor-kappa B, and apoptosis. J Adb Pharm Technol Res 2016;7:99-104. [Crossref]
28. Lima da Cruz RV, Moulin TC, Petiz LL, Leão RN. A single dose of 5-MeO-DMT stimulates cell proliferation, neuronal survivability, morphological and functional changes in adult mice ventral dentate gyrus. Front Mol Neurosci 2018;11:312.doi: 10.3389/fnmol.2018.00312. eCollection 2018. [Crossref]